盐酸普拉克索联合美多芭治疗帕金森病的临床疗效

目的研究联合盐酸普拉克索和美多芭治疗帕金森病的临床疗效及安全性。方法收集帕金森患者110例并随机分为对照组和治疗组。对照组给予美多芭片治疗，治疗组在对照组的基础上给予盐酸普拉克索片，疗程均为12周，于治疗前后分时间点进行UPDRS评分评估治疗效果。结果治疗后对照组总有效率为60％，治疗组总有效率为83．64％：治疗组第12周UPDRS总分和第8、12周UPDRSⅢ评分均值显著低于对照组（P〈0．01），第8周UPDRS总分和第8、12周UPDRSⅡ评分均值低于对照组且有统计学意义（P〈0．05）。结论联合盐酸普拉克索和美多芭治疗帕金森病有效且安全，副作用明显少于单用美多芭，值得临床推广。

Effects of pramipexole hydrochloride combined with madopar in the therapy of parkinsonism

Objective To study the clinical effect and safety of pramipexole hydrochloride combined with madopar in the therapy of parkinsonism.Methods All of 110 patients with parkinson were randomly divided into control group and treatment group.Control group was given madopar tablets;treatment group was given pramipexole hydrochloride tablets on the basis of control group,treatment 12 weeks.Use the UPDRS score to evaluate treatment effects before and after treatment.Results After treatment,the total effective rate of control group was 60%,treatment group was 83.64%;treatment group UPDRS total score at 12 weeks and UPDRSⅢ score at 8、12 weeks of were significantly lower than the control group(P < 0.01);UPDRS total score at 8 weeks and UPDRSⅡ score at 8,12 weeks were lower than the control group(P < 0.05).Conclusion Pramipexole hydrochloride combined with madopar in the therapy of parkinsonism was effective and safe,and side effects were significantly less than single-use madopar,worth promoting.